Guerbet and IBM Watson Health Announce a Second Co-Development Project as Part of their Strategic Partnership for Leveraging Artificial Intelligence in Medical Imaging

IBMGuerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, announced that it has signed a new agreement with IBM Watson Health to co-develop and co-commercialize an artificial intelligence (AI) solution to help clinicians diagnose and monitor patients with prostate cancer. This agreement follows the first agreement signed in July 2018 between the two companies with the aim of using an artificial intelligence program to help clinicians diagnose and monitor patients with liver cancer.

Under this second program, Guerbet and IBM will work to develop a tool using artificial intelligence with the goal of helping to detect, segment, characterize and monitor lesions over time. This AI approach may allow for faster and more informed diagnosis of prostate cancer.

Prostate cancer is the second most commonly diagnosed cancer in men (13.5% of male cancer diagnoses worldwide according to the WHO).(1) The number of prostate MRIs is currently increasing by more than 10% per year, and a 2017 Lancet clinical study(2) has shown that 27% of biopsies may be avoided and 18% of unseen cancers detected by using multiparameter MRI.

"The main diagnostic challenge with prostate cancer lies in identifying cancers requiring rapid treatment and those requiring only active surveillance, while avoiding unnecessary biopsies,"(3) said David Gruen, M.D., Chief Medical Officer, Imaging, IBM Watson Health. "For this reason, optimal patient outcomes depend on the rapid and accurate diagnosis and treatments that AI technologies can potentially help provide."

"The aging of our population has made prostate cancer a global public health problem. Some prostate cancers warrant active therapeutic management while others require only regular monitoring. Augmented intelligence can help enable doctors to diagnose these different cases more rapidly and more accurately, thus helping to potentially reduce the number of unnecessary biopsies and allowing them to propose the most appropriate therapeutic strategy for each patient. We look forward to strengthening our collaboration with IBM Watson Health to expand our portfolio of innovative diagnostic and surveillance solutions in oncology," said Yves L'Epine, CEO of Guerbet.

The AI solution for prostate will be designed for compatibility with most PACS (Picture Archiving and Communication System) visualization systems, which will make its direct integration into the workflows of healthcare professionals that much easier.

"We are excited to further strengthen our partnership with Guerbet that has already been active in liver cancer," said Anne Le Grand, General Manager, Imaging, Life Sciences and Oncology, IBM Watson Health. "This AI solution for prostate will be one in a range of decision support solutions using Watson image analysis, that may potentially help radiologists and oncologists to diagnose conditions and make clinical decisions with patients."

"With IBM Watson Health, we will be leveraging progress made under the initial liver collaboration for the purposes of this second project dedicated to prostate cancer, with the same aim of delivering augmented intelligence to help radiologists and oncologists. This partnership is in line with Guerbet's commitment to developing ambitious medical solutions to speed up diagnosis, improve the patient experience, and reduce clinical risks and costs," said François Nicolas, Chief Digital Officer for Guerbet.

About Guerbet

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018.

About IBM Watson Health

Watson Health is a business unit of IBM that is dedicated to the development and implementation of AI and data-driven technologies to advance health. Watson Health technologies are tackling a wide range of the world's biggest healthcare challenges including cancer, diabetes, drug discovery and more.

1. "Latest global cancer data: Cancer burden rises to 18.1 million new cases and 9.6 million cancer deaths in 2018;" Press Release; The World Health Organization; 12 September 2018
2. (Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Vol. 389, Issue 10071, pp 815-822, February 25, 2017)
3. Active surveillance for prostate cancer: patient selection and management; L. Klotz; Curr Oncol. 2010 Sep; 17(Suppl 2): S11-S17.

Most Popular Now

Using Artificial Intelligence to Predict…

Thyroid nodules are small lumps that form within the thyroid gland and are quite common in the general population, with a prevalence as high as 67%. The great majority of...

Bayer Launches LifeHub UK Focused on Art…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The new hub is the seventh pillar of Bayer's global network...

NHS Health Tech Team of the Year Named

A pioneering NHS trust has been recognised at the 2019 HTN Awards for its innovative work using InterSystems technology to help enhance care for hundreds of thousands of patients. North...

Philips and Klinikum Stuttgart Hospital …

Royal Philips (NYSE:PHG, AEX:PHIA), a global leader in health technology, and German Klinikum Stuttgart hospital, the largest provider in the region, announced they have signed a comprehensive 10-year innovation partnership...

First Entirely Digital Clinical Trial En…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study. The...

Personalised and Powerful: UK to Lead Ne…

The UK will be transformed into a global hub for radiotherapy research, pioneering the use of the latest techniques such as FLASH radiotherapy and artificial intelligence, with a new £56...

Innovations for Tomorrow's Healthcare - …

18 - 21 November 2019, Düsseldorf, Germany. Groundbreaking innovations shape tomorrow's medical progress. At this year's MEDICA, visitors can find out what these exemplary innovations will be like in the here...

SilverCloud Health Marks World Mental He…

More than 300,000 people suffering with mental health disorders such as anxiety and depression have now been treated through innovative digital therapy programmes developed as a result of a partnership...

Siemens Healthineers Launches ACUSON Red…

Siemens Healthineers has launched the ACUSON Redwood, a new ultrasound system built on the company's new platform architecture and features advanced applications for greater clinical confidence, AI-powered tools for smart...

Nuance and Microsoft Partner to Transfor…

Nuance Communications Inc. and Microsoft Corp. have joined forces to help transform healthcare delivery for a more sustainable future. Together, the companies will accelerate the delivery of ambient clinical intelligence...

AI Predicts which Pre-Malignant Breast L…

New research at Case Western Reserve University could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast...

MEDICA 2019 + COMPAMED 2019 Bring in ove…

18 - 21 November 2019, Düsseldorf, Germany. More dynamic, more digital and more networked than ever: the medical industry is taking strides into the future. If you want to be in...